Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Department of Nursing, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Sci Rep. 2023 Jul 31;13(1):12382. doi: 10.1038/s41598-023-39372-3.
Human Epidermal Growth Factor Receptor-2 (HER2)-negative breast cancers (BCs) contain HER2-low and HER2-zero ones. HER2-low breast cancer has been receiving wide-spread concerns as the marvelous effect of novel anti-HER2 antibody-drug conjugates, however, the characteristic remains unknown. Our aim was to explore the differences of clinicopathological indicators and survival outcomes between HER2-low and HER2-0 breast cancers. We retrospectively analyzed 501 invasive breast cancer patients with complete data on HER2 status from 2017 to 2021 in our single center, of whom 415 HER2 negative patients were included for subsequent analysis. Each cohort was further divided into hormone receptor (HR) positive and HR negative subgroup. Clinicopathological factors and survival outcomes were collected and compared between HER2-low BCs and HER2-0 BCs. HER2-low BCs was obviously higher in HR positive BCs, with 277 (90.5%) HER2-low HR positive patients, 29 (9.5%) HER2-low HR negative patients, 68 (62.4%) HER2-0 HR positive patients and 41 (37.6%) HER2-0 HR negative patients (P < 0.001). Significant differences between HER2-low BCs and Her2-0 BCs were observed in lymph node ratio (LNR) (mean rank, 215 vs. 188 P = 0.014), estrogen receptor (ER)expression (90.5% vs. 62.4% P < 0.001), progesterone receptor (PR) expression (84.3% vs. 56.9% P < 0.001), Ki-67 expression (46.4% vs. 61.5% P < 0.001), androgen receptor (AR) expression (68% vs. 50.5% P < 0.001), adjuvant chemotherapy (69% vs. 79.8% P = 0.03). HER2-low BCs had lower histological grade than HER2-0 BCs, with grade I-II (68.7% vs. 43.1%) and grade III (22.2% vs. 43.1%) P < 0.01. No statistical differences were detected between the two groups for DFS and DDFS. Our results demonstrated that HR and AR status was closely related to HER2-low breast cancers. Further exploration about survival prognosis of HER2-low breast cancer is badly needed.
人表皮生长因子受体 2（HER2）阴性乳腺癌（BC）包括 HER2 低表达和 HER2 零表达。新型抗 HER2 抗体药物偶联物的显著疗效引起了 HER2 低表达乳腺癌的广泛关注，但其特征尚不清楚。我们旨在探讨 HER2 低表达和 HER2 零表达乳腺癌之间临床病理指标和生存结局的差异。我们回顾性分析了 2017 年至 2021 年在我院就诊的 501 例 HER2 状态完整的浸润性乳腺癌患者，其中 415 例 HER2 阴性患者纳入后续分析。每个队列进一步分为激素受体（HR）阳性和 HR 阴性亚组。收集并比较了 HER2 低表达 BC 和 HER2 零表达 BC 之间的临床病理因素和生存结局。HER2 低表达 BC 在 HR 阳性 BC 中明显更高，其中 277 例（90.5%）HER2 低表达 HR 阳性患者、29 例（9.5%）HER2 低表达 HR 阴性患者、68 例（62.4%）HER2 零表达 HR 阳性患者和 41 例（37.6%）HER2 零表达 HR 阴性患者（P<0.001）。HER2 低表达 BC 和 HER2 零表达 BC 之间在淋巴结比值（LNR）（平均秩，215 比 188，P=0.014）、雌激素受体（ER）表达（90.5%比 62.4%，P<0.001）、孕激素受体（PR）表达（84.3%比 56.9%，P<0.001）、Ki-67 表达（46.4%比 61.5%，P<0.001）、雄激素受体（AR）表达（68%比 50.5%，P<0.001）和辅助化疗（69%比 79.8%，P=0.03）方面存在显著差异。与 HER2 零表达 BC 相比，HER2 低表达 BC 的组织学分级较低，I 级-II 级（68.7%比 43.1%）和 III 级（22.2%比 43.1%）比例更高（P<0.01）。两组之间的无病生存（DFS）和无远处转移生存（DDFS）无统计学差异。我们的研究结果表明，HR 和 AR 状态与 HER2 低表达乳腺癌密切相关。迫切需要进一步探讨 HER2 低表达乳腺癌的生存预后。
